News

Alzheimer’s Association Funds 2-Year Extension of Study that Explores Intensive Blood Pressure Treatment on Dementia Risk

The Alzheimer’s Association has funded a two-year extension of the SPRINT-MIND study — SPRINT MIND 2.0 — to further explore the role of intensive treatment to lower blood pressure and the risk of dementia. The funding, which totals more than $800,000, will allow researchers to follow the participants of the original trial for…

UB-311 Vaccine Safe, Effective in Mild Alzheimer’s Patients, Phase 2a Trial Suggests

United Neuroscience’s Alzheimer’s vaccine candidate UB-311 was found safe and well-tolerated, triggering an antibody response against beta-amyloid in most of the patients, according to Phase 2a trial results. “These early results suggest a clinical response and support the continued and rapid development of UB-311. The intent of this Phase 2a study was to…

Top 10 Alzheimer’s Disease Stories of 2018

Throughout 2018, Alzheimer’s News Today brought you stories of important discoveries, treatment developments, clinical trials, and other events related to Alzheimer’s disease. As we look forward to providing more news to those living with Alzheimer’s as well as their family members and caregivers this year, here are the 10 most-read stories…